238 related articles for article (PubMed ID: 9849822)
1. Ipamorelin, the first selective growth hormone secretagogue.
Raun K; Hansen BS; Johansen NL; Thøgersen H; Madsen K; Ankersen M; Andersen PH
Eur J Endocrinol; 1998 Nov; 139(5):552-61. PubMed ID: 9849822
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide.
Doi N; Hirotani C; Ukai K; Shimada O; Okuno T; Kurasaki S; Kiyofuji T; Ikegami R; Futamata M; Nakagawa T; Ase K; Chihara K
Arzneimittelforschung; 2004; 54(12):857-67. PubMed ID: 15646370
[TBL] [Abstract][Full Text] [Related]
3. Desensitization studies using perifused rat pituitary cells show that growth hormone-releasing hormone and His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 stimulate growth hormone release through distinct receptor sites.
Blake AD; Smith RG
J Endocrinol; 1991 Apr; 129(1):11-9. PubMed ID: 1674284
[TBL] [Abstract][Full Text] [Related]
4. A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.
Ankersen M; Johansen NL; Madsen K; Hansen BS; Raun K; Nielsen KK; Thogersen H; Hansen TK; Peschke B; Lau J; Lundt BF; Andersen PH
J Med Chem; 1998 Sep; 41(19):3699-704. PubMed ID: 9733495
[TBL] [Abstract][Full Text] [Related]
5. Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.
Van den Berghe G; de Zegher F; Bowers CY; Wouters P; Muller P; Soetens F; Vlasselaers D; Schetz M; Verwaest C; Lauwers P; Bouillon R
Clin Endocrinol (Oxf); 1996 Sep; 45(3):341-51. PubMed ID: 8949573
[TBL] [Abstract][Full Text] [Related]
6. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH.
Arvat E; di Vito L; Maccagno B; Broglio F; Boghen MF; Deghenghi R; Camanni F; Ghigo E
Peptides; 1997; 18(6):885-91. PubMed ID: 9285939
[TBL] [Abstract][Full Text] [Related]
7. Effect of intravenous or intracerebroventricular injections of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 on GH release in conscious, freely moving male rats.
Yagi H; Kaji H; Sato M; Okimura Y; Chihara K
Neuroendocrinology; 1996 Feb; 63(2):198-206. PubMed ID: 9053785
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterisation of a new oral GH secretagogue, NN703.
Hansen BS; Raun K; Nielsen KK; Johansen PB; Hansen TK; Peschke B; Lau J; Andersen PH; Ankersen M
Eur J Endocrinol; 1999 Aug; 141(2):180-9. PubMed ID: 10427162
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone.
Bowers CY; Reynolds GA; Durham D; Barrera CM; Pezzoli SS; Thorner MO
J Clin Endocrinol Metab; 1990 Apr; 70(4):975-82. PubMed ID: 2108187
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone (GH)-releasing peptide and GH releasing hormone stimulate GH release from subpopulations of somatotrophs in rats.
Mitani M; Kaji H; Abe H; Chihara K
J Neuroendocrinol; 1996 Nov; 8(11):825-30. PubMed ID: 8933359
[TBL] [Abstract][Full Text] [Related]
11. Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro.
Jiménez-Reina L; Cañete R; de la Torre MJ; Bernal G
Histol Histopathol; 2002; 17(3):707-14. PubMed ID: 12168778
[TBL] [Abstract][Full Text] [Related]
12. Activation of the hypothalamo-pituitary-adrenal axis by the growth hormone (GH) secretagogue, GH-releasing peptide-6, in rats.
Thomas GB; Fairhall KM; Robinson IC
Endocrinology; 1997 Apr; 138(4):1585-91. PubMed ID: 9075719
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of action of a second generation growth hormone-releasing peptide (Ala-His-D-beta Nal-Ala-Trp-D-Phe-Lys-NH2) in rat anterior pituitary cells.
Akman MS; Girard M; O'Brien LF; Ho AK; Chik CL
Endocrinology; 1993 Mar; 132(3):1286-91. PubMed ID: 8095015
[TBL] [Abstract][Full Text] [Related]
14. Intranasal administration of His-D-Trp-Ala-Trp-D-Phe-LysNH2 (growth hormone releasing peptide) increased plasma growth hormone and insulin-like growth factor-I levels in normal men.
Hayashi S; Okimura Y; Yagi H; Uchiyama T; Takeshima Y; Shakutsui S; Oohashi S; Bowers CY; Chihara K
Endocrinol Jpn; 1991 Feb; 38(1):15-21. PubMed ID: 1915110
[TBL] [Abstract][Full Text] [Related]
15. Oral activity of the growth hormone releasing peptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 in rats, dogs and monkeys.
Walker RF; Codd EE; Barone FC; Nelson AH; Goodwin T; Campbell SA
Life Sci; 1990; 47(1):29-36. PubMed ID: 2117689
[TBL] [Abstract][Full Text] [Related]
16. Effect of growth hormone (GH)-releasing peptide (GHRP) on the release of GH from cultured anterior pituitary cells in cattle.
Soliman EB; Hashizume T; Kanematsu S
Endocr J; 1994 Oct; 41(5):585-91. PubMed ID: 7889121
[TBL] [Abstract][Full Text] [Related]
17. The synergistic effects of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 on growth hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 3',5'-monophosphate accumulation in rat primary pituitary cell culture.
Cheng K; Chan WW; Barreto A; Convey EM; Smith RG
Endocrinology; 1989 Jun; 124(6):2791-8. PubMed ID: 2541999
[TBL] [Abstract][Full Text] [Related]
18. Effects of growth hormone-releasing peptides in healthy dogs and in dogs with pituitary-dependent hyperadrenocorticism.
Bhatti SF; De Vliegher SP; Van Ham L; Kooistra HS
Mol Cell Endocrinol; 2002 Nov; 197(1-2):97-103. PubMed ID: 12431802
[TBL] [Abstract][Full Text] [Related]
19. Influence of endogenous cholinergic tone and alpha-adrenergic pathways on growth hormone responses to His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 in the dog.
Muruais J; Peñalva A; Dieguez C; Casanueva FF
J Endocrinol; 1993 Aug; 138(2):211-8. PubMed ID: 8228729
[TBL] [Abstract][Full Text] [Related]
20. Decreased GH secretion and enhanced ACTH and cortisol release after ghrelin administration in Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH.
Correa-Silva SR; Nascif SO; Lengyel AM
Pituitary; 2006; 9(2):101-7. PubMed ID: 16832586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
